Xilio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Xilio Therapeutics Inc XLO.OQ reported a quarterly adjusted loss of 16 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -24 cents. The mean expectation of two analysts for the quarter was for a loss of 8 cents per share. Wall Street expected results to range from -10 cents to -6 cents per share.

• Revenue rose 243% to $8.08 million from a year ago; analysts expected $8.21 million.

• Xilio Therapeutics Inc's reported EPS for the quarter was a loss of 16 cents​.

• The company reported a quarterly loss of $15.84 million.

• Xilio Therapeutics Inc shares had risen by 5.1% this quarter and lost 25.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 64.3% above its last closing price of $0.71

This summary was machine generated from LSEG data August 14 at 12:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)